ISSN (O) 2693-5007

A Systematic Review of the Effectiveness of Acetylcholinesterase Inhibitors on Cognition for Patients with Alzheimer's Disease

Lena Meziou¹* | Kevin Haubrick¹

Abstract

OPEN ACCESS

Research Review (Wilmington, N.C.) DOI: https://doi.org/10.52845/RR/2024-5-6-1

Res Rev (Wilmington, N.C.) 5 (6), 2618-2639 (2024)

REVIEW ARTICLE

Received 20 Apr 2024 | Revised 17 May 2024 | Accepted 15 June 2024 | Online Available 20 June 2024

This systematic review evaluates the effectiveness of acetylcholinesterase inhibitors (AChEIs) including donepezil, galantamine, and rivastigmine in delaying cognitive decline in Alzheimer's disease (AD) patients. It addresses three primary objectives: overall efficacy assessment, comparison of cognitive benefits across AChEI types, and identification of research gaps. The review, comprising 45 selected articles, reveals consistent evidence of AChEI efficacy in improving cognitive outcomes in AD. While higher AChEI doses show potential for greater cognitive improvement, they also elevate the risk of adverse effects. Donepezil is noted for memory enhancement and slowing cognitive decline, galantamine for memory and attention, and rivastigmine for executive function improvement.

Key words: acetylcholinesterase inhibitors, Alzheimer's disease, cognition, donepezil, galantamine, rivastigmine 2

1 | INTRODUCTION

Dementia is a clinical syndrome of progressively worsening cognitive impairment and functional deterioration (Duong et al., 2017). There are roughly 47 million people with dementia around the world, of whom 5.5 million live in the United States. By 2030, this figure is predicted to reach 75 million people around the world, and it is projected to triple by 2050 (Ulep et al., 2018). The health and long-term care systems have been estimated to have spent \$259 billion on dementia care in 2017 (Olivari et al., 2018).

Alzheimer's disease (AD), the sixth most prevalent cause of mortality in the US, is the most common type of dementia (Skaria, 2022). Several factors increase the risk of developing AD such as cerebrovascular disorders, diabetes, hypertension, obesity, dyslipidemia, cognitive reserve, physical activity, and dietary habits (Silva et al., 2019). Extracellular amyloid plaques, intracellular neurofibrillary tangles, deteriorated synapses, and neuronal death are the main neuropathologic indicators of AD (Ulep et al., 2018). An accumulation of amyloid plaques disrupts synaptic activity and sets off a chain of subsequent events that lead to intraneuronal and intraneuronal dysfunction and eventually result in cell death (Ulep et al., 2018).

For the screening, diagnosis, and management of Alzheimer's disease patients, healthcare providers must be able to quickly and accurately identify the symptoms and pathology of the disease that are associated with Alzheimer's disease (Porsteinsson et al., 2021). Additionally, this allows patients as well as caregivers to make necessary lifestyle modifications that may prolong the enhancement of the patient's quality of life. Thus, more effective research is required on AD-modifying methods of treatment, such as acetylcholinesterase inhibitors, along

¹The University of Houston.

Supplementary information The online version of this article (https://doi.org/10.52845/RR/2024-5-6-1) contains supplementary material, which is available to authorized users. Lena Meziou et al., 2024; Published by Research Review, Inc. This Open Access article is distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



Research Review

Address correspondence to: Lena, Meziou, The University of Houston, Email: @lena.meziou

with risk-reduction strategies to improve or stabilize AD symptoms. This review aims to examine the effectiveness of acetylcholinesterase inhibitors (donepezil, galantamine, and rivastigmine) in delaying the worsening of cognitive functions associated with the disease.

Objectives

1. To determine the overall efficacy of acetylcholinesterase inhibitors in improving cognitive functions among individuals with Alzheimer's disease

2. To compare the cognitive benefits of different types of acetylcholinesterase inhibitors (donepezil, galantamine, and rivastigmine) in Alzheimer's disease patients.

3. To identify gaps in current literature related to the cognitive effects of acetylcholinesterase inhibitors in Alzheimer's disease, suggesting areas of future research and study improvement.

2 | METHODS

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines are used in this systematic review to assess qual-

Table 1.	Key	words	and	MeSH	terms
Table 1.	NC	worus	anu	INICOLL	terms

itative information on the effectiveness of acetylcholinesterase inhibitors on Alzheimer's disease patients (Page et al., 2021).

2.1 | Protocol and Registration

This systematic review was registered with PROS-PERO, the International Prospective Register of Systematic Reviews (registration #443631).

2.2 | Search Strategy

A thorough scientific literature search was conducted using online databases to find peer-reviewed research articles published between 2003 to 2024 for this systematic review. Two online databases were used, PubMed and EMBASE. Table 1 lists a combination of keywords and MeSH terms that were employed. The search strategy was designed to find studies relevant to Alzheimer's disease and acetylcholinesterase inhibitors. The search terms were strategically combined and expanded using Boolean operators (AND, OR) as shown in Table 2. Some reference lists of relevant articles were searched as well to find any additional research articles that might have been overlooked.

OLDER ADULTS,	ALZHEIMER'S, ALZHEIMERS, ALZHEIMER,	ACETYLCHOLINESTERASE	COGNITIVE FUNCTIONS,
SENIORS,	DEMENTIA, COGNITIVE IMPAIRMENT,	INHIBITORS, CHOLINESTERASE	COGNITIVE ABILITIES,
ELDERLY, AGED,	COGNITIVE DECLINE,	INHIBITORS, DONEPEZIL,	MEMORY, DECISION
GERIATRIC	NEURODEGENERATIVE DISORDER	GALANTAMINE, RIVASTIGMINE	MAKING, ATTENTION

Table 2. Boolean Operators(AND, OR)

Search equation using Boolean operators

(``older adults'' OR ``seniors'' OR ``elderly'' OR ``aged'' OR ``geriatric'') AND (``Alzheimer's'' OR ``Alzheimers'' OR ``Alzheimer'' OR ``dementia'' OR ``cognitive impairment'' OR ``cognitive decline'' OR ``neurodegenerative disorder'') AND (``acetylcholinesterase inhibitors'' OR ``cholinesterase inhibitors'' OR ``donepezil'' OR ``galantamine'' OR ``rivastigmine'') AND (``cognitive functions'' OR ``cognitive abilities'' OR ``memory'' OR ``decision making'' OR ``attention'')

2.3 | Eligibility Criteria

Research articles were included based on specific eligibility criteria which are outlined in Table 3.

Only primary research studies were considered for inclusion in this systematic review. Clinical trials and randomized controlled trials (RCTs) were eligible for inclusion while case studies, systematic

reviews, and meta-analysis were excluded. Participants involved female and male older adults aged 55+ years diagnosed with Alzheimer's disease. Patients aged less than 55 years old without a diagnosis of cognitive impairment or Alzheimer's disease are excluded. Studies that evaluated the effects of acetylcholinesterase inhibitors were eligible while studies that evaluated other medications/inhibitors were excluded. Studies that reported outcomes related to cognitive functions were included since cognitive impairment causes several cognitive changes that negatively affect the patient's quality of life. Studies that failed to report any type of cognitive function were excluded. Only studies published in the English language between 2003 to 2024 were considered for inclusion.

Criteria	Inclusion	Exclusion
Study Design	Clinical trials and RCT	Case studies and systematic reviews
Preference		
Participants' Age	Older adults (55+ years)	Less than 55 years
Participants'	Patients with Alzheimer's disease	Other than Alzheimer's (such as Parkinson's
Condition		disease)
Size of Study	>= 10 in each study group	< 10 in each study group
Groups		
Exposure	Acetylcholinesterase inhibitors (donepezil,	Medications/inhibitors other than
	galantamine, and rivastigmine)	Acetylcholinesterase inhibitors
Outcomes	Cognitive functions (such as attention, memory, and	Non-cognitive functions
	decision making)	
Language	Limited to articles in English	
Publication Year	2003-2024	
Range		

Table 3. Inclusion/ExclusionCriteria

2.4 | Data Extraction and Quality Assessment

The articles' titles and abstracts were evaluated by the primary author for their applicability to the research question. Full-text articles of potentially pertinent research were then assessed for their eligibility. A study was included based on the predetermined criteria. Studies were excluded if they failed to meet the inclusion criteria or if they were duplicate articles. To represent the study selection process, including the number of records identified, screened, and included, a PRISMA flowchart, shown in Figure 1, was created (Moher et al., 2009).

A data extraction table was adapted from the Cochrane template (Ryan et al., 2016). Information extracted included the author, date of publication, study design, the purpose of the study, participants' characteristics, study methods, description, intervention description, outcome measures, conclusions, and bias rating. Additional research articles from the same study were used to find any missing data.

The Academy of Nutrition and Dietetics Quality Cri-

teria Checklist was used to assess the quality and risk of bias in primary research (Academy of Nutrition and Dietetics, 2016). Each article was evaluated for objectivity and scientific suitability based on several factors, including research question, participant selection, blinding, outcomes, results, and more. After evaluation, each article was then marked as positive, negative, or neutral. A positive mark shows that concerns of inclusion/exclusion, bias, generalizability, data collection, and analysis have been effectively addressed in the study. A negative mark shows that the issues mentioned have not been fully addressed. A neutral mark shows that the report is neither particularly strong nor particularly weak.

3 | RESULTS

3.1 | Study Selection

Two database searches led to a total of 172 articles. The inclusion criteria were applied to the titles and abstracts and duplicates were removed; 154 articles were selected for full-text screening. Articles were

removed if they did not meet the inclusion criteria (for example, the outcome was not part of cognitive functions, diseases other than Alzheimer's were studied and were irrelevant to the main subject). Forty-five clinical trials and randomized controlled trials met the eligibility criteria, examined the effec-

3.2 | Study Characteristics

The selected studies were conducted between 2003 and 2024. Sample sizes ranged from 59 to 784 participants with Alzheimer's disease (AD). The mean age of participants across the studies ranged from 45 to 90 years and the majority were diagnosed with mild to moderate Alzheimer's disease. The duration of treatment varied between six weeks to 12 months, with an average follow-up period of 12 months.

3.3 | Assessment Tools for Cognitive Outcomes

Across the 45 included studies, various assessment tools for cognitive outcomes were used, with

3.4 | Donepezil Cognitive Outcomes

Among the included studies, 13 studies examined the effectiveness of donepezil in delaying the worsening of cognitive functions associated with the disease as shown in Table 5. Black et al. (2007), Feldman et al. (2003), and Molinuevo et al. (2009) found patients with severe AD who took donepezil maintained cognitive performance for at least six months while Wallin et al. (2006), showed three years of donepezil medication resulted in significant favorable cognitive and behavioral results (p<0.001). Boada-Rovira et al. (2004) noted donepezil treatment resulted in statistically significant improvements (p<0.0001) in cognition, patient activity, and social behavior, and was generally well tolerated compared with baseline over 12 weeks. Boada-Rovira and his team (2004) also highlighted donepezil was associated with substantial enhancements in patient social contact and engagement (p<0.0001). Similarly, Feldman et al. (2005) reported significant improvement in patient participation in activities of daily living (p<0.001) and cognition (p<0.0002).

Johannsen et al. (2006), Winblad et al. (2006),

tiveness of acetylcholinesterase (AChE) inhibitors in delaying the worsening of cognitive functions associated with AD, and were included in this systematic review. A table summary of outcomes including the risk of bias evaluation is included (Tables 5, 6, 7, and 8).

the most used tools being the Mini-Mental State Examination (MMSE) and the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog). The MMSE was the most frequently used tool, used in 67% of the studies, followed by the ADAS-Cog, used in 44% of the studies, followed by the Severe Impairment Battery (SIB), used in 16% of the studies. Other assessment tools such as Clinical Dementia Rating (CDR), Computerized Neuropsychological Test Battery (CNTB), Digit Symbol Substitution Test (DSST), Consortium to Establish a Registry for Alzheimer's Disease Battery (CERAD), and Neuropsychological Test Battery were used in fewer studies. Table 4 provides an overview of the studies using each assessment tool.

and Howard et al. (2012) concluded a definite therapeutic advantage was shown during patients' initial donepezil medication and when the medication period was completed. Johannsen et al. (2006) found at week 12, the donepezil treatment group experienced significantly greater improvement (p=0.02) in cognition scores as compared with the placebo group.

Howard et al. (2012) noted significant improvement (p<0.001) in cognition and behavior was seen for individuals who kept their donepezil treatment as compared with those assigned to discontinue it.

Sabbagh et al. (2003) and Han et al. (2016) compared donepezil 23 mg/day with 10mg/day and found donepezil 23 mg/d produced statistically significant cognitive gains (p=0.011 and p=0.028, respectively) as compared to 10 mg/d of donepezil. The cognitive benefits of a higher concentration of donepezil were particularly apparent in patients with more advanced disease stages. Homma et al. (2008) also noted donepezil (5mg/day and 10mg/day) showed statistically significant superiority (p<0.001) in cognition compared to placebo at 8, 16, and 24 weeks. On the




Fig. 1: PRISMA 2020 Flow Diagram

other hand, Doody et al. (2008) suggested there were no significant differences between a higher dose or a standard dose of donepezil on cognitive skills or reasoning. Doody et al. (2009) also found cognitive scores from baseline to week 12 improved (p<=0.05) but to week 24, scores worsened (p=0.05). Although Sabbagh et al. (2003) and Han et al. (2016) indicate a significant cognitive advantage of a higher dose of donepezil, findings from Doody et al. (2008) suggest no substantial difference between higher and standard doses in cognitive outcomes. Overall, donepezil treatment demonstrated significant cognitive benefits, particularly in maintaining and improving cognitive performance, patient engagement, and activity of daily lives in patients with AD.

Table 4. Studies Using Assessment Tools

Assessment Tool	Studies Using the Tool
Mini-Mental State Examination	Sabbagh et al. (2012), Karaman et al. (2004), Wilcock et al. (2003), Johansen et al. (2006),
	Black et al. (2007), Feldman et al. (2007), Boada-Rovira et al. (2004), Feldman et al. (2005),
	Brodaty et al. (2006), Baakman et al. (2021), Almkvist et al. (2004), Bullock et al. (2005),
	Olazaran et al. (2005), Feldman & Lane (2007), Jones et al. (2004), Doody et al. (2008),
	Howard et al. (2012), Grossberg et al. (2004), Gorus et al. (2007), Molinuevo et al. (2009),
	Wattmo et al. (2012), Lopez-Pousa et al. (2005), Wallin et al. (2006), Calabria et al. (2008),
	Aguglia et al. (2004), Cerci et al. (2007), Connelly et al. (2004), Xu et al. (2021), Sun et al. (2007)
Alzheimer's Disease	Karaman et al. (2004), Wilcock et al. (2003), Johansen et al. (2006), Feldman et al. (2007),
Assessment Scale-Cognitive	Gaudig et al. (2011), Brodaty et al. (2006), Doody et al. (2009), Olazaran et al. (2005),
Subscale	Feldman & Lane (2007), Richarz et al. (2014), Jones et al. (2004), Doody et al. (2008),
	Lyketsos et al. (2004), Grossberg et al. (2004), Wallin et al. (2006), Pirttila et al. (2003),
	Aguglia et al. (2004), Song et al. (2004), Mintzer & Kershaw (2002)
Severe Impairment Battery	Black et al. (2007), Feldman et al. (2005), Winblad et al. (2006), Bullock et al. (2005), Homma et al. (2008), Burns et al. (2009), Ha et al. (2016)
Clinical Dementia Rating	Feldman et al. (2007), Doody et al. (2009), Sun et al. (2007)
Computerized	Caramelli et al. (2004)
Neuropsychological Test Battery	
Digit Symbol Substitution Test	Connelly et al. (2004)
Consortium to Establish a	Crowell et al. (2005)
Registry for Alzheimer's Disease	
Battery	
Neuropsychological Test Battery	Rozzini et al. (2006)

3.5 | Galantamine Cognitive Outcomes

Among the included studies, 11 studies examined the effectiveness of galantamine in delaying the worsening of cognitive functions associated with AD as shown in Table 6. Burns et al. (2009) found galantamine significantly improved cognitive functioning, especially in the domains of memory, visuospatial ability, and attention (p=0.006, p=0.002, p=0.076; respectively). Gaudig et al. (2011), Brodaty et al. (2006), Richarz et al. (2014), and Lyketsos et al. (2004) showed galantamine medication improved patients' cognition with mild to advanced moderate AD. Brodaty et al. (2006) noted 65% of patients' cognitive scores either improved "slightly, much, or very much." Although Gaudig et al. (2011) and Lykestsos et al. (2004) discovered withdrawal of galantamine is associated with a decline in cognitive scores (p=0.001, p=0.0002, respectively), Richarz et al. (2014) found cognition remained improved after three years compared with an untreated population (p<0.05). Like the findings of Richarz and his team (2014), Pirtilla et al. (2003) highlighted the administration of 12 mg/day of galantamine twice a day

improved cognitive function for up to three years (p<0.05, p<0.001, respectively).

Although Mintzer & Kershaw (2003) showed patients treated with 16mg/day achieved statistically improved cognitive scores (p=0.003), Baakman et al. (2021) demonstrated patients treated with 16 mg/day of galantamine led to slow theta and delta waves which are associated with lower cognitive functioning in AD patients (p=0.0001), while Caramelli et al. (2004) discovered no significant differences (p=0.673) in cognition scores between weeks 12 and baseline for those treated with 16mg/day of galantamine. Gorus et al. (2007) noted similar results with individuals suffering from mild to moderate AD receiving galantamine treatment had improved memory and language (p=0.695, p=0.012, respectively) for at least five months. Song et al. (2014) also added galantamine treatment led to improvements in attention (p=0.036) and language cognition areas (p<0.001). Galantamine treatment shows beneficial effects on cognitive functioning, particularly memory, visuospatial ability, and attention, across various stages of AD.

Black	Study Design: 24-week,	To evaluate the efficacy and safety	Patients with severe AD who took	R/+;
et	randomized, double-blind	of donepezil for severe Alzheimer	donepezil maintained cognitive	V/+
al.,	controlled trial. Patients were	disease.	performance for at least 6 months	
2007	randomized to donepezil 10mg/day		in contrast to those who took a	
	or placebo for 24 weeks.		placebo, who had a 10% decline	
	Sample Design:		from baseline (p=0.0001).	
	343 ambulatory or			
	ambulatory-aided individuals, aged			
	50 or older, with likely AD.		S 1 12 1 1 1 1	. /
	- Study Design: 12-week, open-label	To evaluate the efficacy, tolerability,	Donepezil treatment resulted in	R/+;
	trial. Patients received 5mg/day	and safety of donepezil in a wider	statistically significant	V/+
et	donepezil for the first 28 days, this	and more diverse sample of	improvements in cognition, patient	
al.,	dose then increased to 10mg/day.	patients and centers.	activity, and social behavior	
2004	Sample Design: 1113 patients with AD, have good eyesight and hearing		(p<0.0001) and enhancements in	
	independently mobile or with		patient social contact, engagement, and participation in ADL	
	assistance.		(p<0.0001).	
Doody	Study Design: 24-week,	To evaluate the safety and	Donepezil is effective in cognition	R/+;
et	randomized, double-blind	tolerability of donepezil at doses of	and other impacted domains at	V/Æ
al.,	controlled study. Patients received	15 and 20 mg/day.	higher doses. Higher doses of	v/~
2008	either donepezil 10mg/day +	15 414 20 116/443.	donepezil were linked to a more	
2000	5mg/day for weeks 1-12 or		significant cognitive effect.	
	15mg/day for weeks 1-12;			
	20mg/day for weeks 12-24.			
	Sample Design: 31 ambulatory or			
	ambulatory-aided patients, 50-86			
	years old, mild to moderate AD, had			
	been taking donepezil 10 mg/day			
	for 12–30 months.			
Doody	Study Design: 51-week randomized	To examine the impact of a	While there was no change in the	R/+;
et	controlled study. Patients received	48-week donepezil course in	major measure of global function,	V/+
al.,	either 5 mg/day donepezil for 6	amnestic mild cognitive	donepezil showed a slight but	
2009	weeks, then 10 mg/day for 42	impairment, Alzheimer's disease.	substantial improvement on the	
	weeks or a placebo for 48 weeks.		primary measure of cognition	
	Sample Design: 821 patients, 45-90		(p <= 0.5) to week 12 but not to	
	year-old ambulatory or		week 24 (p=0.05)	
	ambulatory-aided with MCI and no			
	infarctions, infections, or concomitant diseases.			
Feld-	Study Design: 24-week	To investigate the efficacy of	Donepezil maintains functional	R/+;
man	randomized, double- blind	donepezil treatment on activities of	ability and cognition for at least six	V/Æ
et	controlled study. Patients received	daily living (ADLs) and social	months in patients with AD. In	V/AL
al.,	donepezil (5mg/day for 4 weeks	functioning in patients with	these patients, donepezil showed a	
2003	and 10mg/day) or placebo for 24	moderate to severe Alzheimer's	considerably slower decline in	
2005	weeks.	disease (AD) and the possible	instrumental and fundamental	
	Sample Design: 290 patients with	benefits of this treatment on	ADLs than placebo.	
	probable AD, could walk	caregiving time and stress levels.	· · · · · · · · ·	
	independently or with assistance.			
Feld-	Study Design: Randomized	To examine the efficacy and safety	Donepezil had statistically	R/+;
man	controlled trial. Patients received	of donepezil in patients with more	significant improvements on	V/+
et	5mg/day donepezil followed by an	severe Alzheimer's disease	cognitive, functional, and	
al.,	increase to 10mg/day or placebo		behavioral measures (p=0.0002) as	
2005	for 28 days.		well as patient participation in	
	Sample Design: 290 ambulatory or		activities of daily living (p<0.001).	
	ambulatory-aided patients with			
	probable AD.			

Table 6. Part B

Table 6	. Part B			
Han et al., 2016	Study Design: 12-month open-label trial. Patients were randomly assigned to donepezil 23 mg or donepezil 10 mg/day for 24 weeks. Sample Design: 223 Asian patients with probable AD and taking donepezil 10 mg/day for 3 months before the study.	To evaluate the safety and effectiveness of donepezil 23 mg/day compared to donepezil 10 mg/day in Asian patients with moderate-to-severe Alzheimer's disease, as well as to examine changes in cognitive and global functioning.	Cognitive improvement was statistically higher with donepezil 23 mg compared to donepezil 10 mg (p=0.028). In terms of global function, there was no distinction between the groupings.	R/+; V/Æ
Homm et al., 2008	 astudy Design: 24-week, randomized controlled, double-blind trial. Patients were randomly assigned to receive donepezil 5 mg, 10 mg, or a placebo. Sample Design: 302 ambulatory or ambulatory-aided AD patients, >= 50 years old, have a caregiver 3 days/week or more, and swallow pills. 	To evaluate the efficacy and tolerability of donepezil in severe Alzheimer's disease (AD).	This study established a significant superiority in cognition (p<0.001) and validated the efficacy of donepezil 5mg/day or 10 mg/day in patients with AD at weeks 8, 16, and 24.	R/+; V/Æ
Howar et al., 2012	rdStudy Design: 52- weeks, double-blind clinical trial. Participants were randomly assigned to 10mg donepezil daily or 5 mg weeks 1-4 or stopping donepezil and starting memantine or continuing donepezil and start memantine. Sample Design: 295 patients with probable AD, have caretakers, prescribed donepezil for >3 months, no severe or unstable medical problems, and not taking memantine.	To assess the continuation of treatment benefits after the progression of Alzheimer's disease to moderate-to-severe.	Patients designated to keep receiving donepezil, as compared with those that stopped receiving donepezil, had a better cognition. Over the course of a year, continuing therapy with donepezil was linked with cognitive advantages (p<0.001) among individuals with moderate or severe Alzheimer's disease.	R/+; V/+
Johan et al. <i>,</i> 2006	nSendy Design: 12-24-week open-label donepezil-treatment; 12-week randomized, double-blind phase; and 12-week single-blind phase. Sample Design: Patients with probable AD, >= 50 years old, ambulatory, good eyesight and hearing, and living at home or in an assisted home care facility.	To determine the value of continued donepezil treatment in patients with Alzheimer's disease for whom the therapeutic benefit was first thought to be questionable.	Most patients showed a definite therapeutic advantage during their initial donepezil medication. Improvement in cognition (p=0.02) and behavior was seen for individuals who kept their donepezil treatment compared to the group that switched to placebo at week 12.	R/+; V/+
Molin- uevo et al., 2011	 Study Design: 6-month prospective, observational, multicenter study. Patients received 1.8 mg/day of donepezil. Sample Design: 408 patients, with probable AD, aged >=55, no prior ChEI treatment, no neurological conditions, and no past alcohol or drug use/abuse. 	To compare the cognitive and functional effects of donepezil therapy in individuals with mild vs moderate Alzheimer's disease (AD).	At 6 months, cognition stays steady in patients receiving donepezil monotherapy. The mild AD group benefits more from donepezil than the moderate AD group, with gains in memory and language domains and a more gradual decrease in ADL (p<0.0001).	R/+; V/+

2625

Table 7. Part C

Sab-	Study Design: 24-week,	To investigate relationships	Regardless of the patient's age,	R/+;
bagh et	randomized, double-blind, trial. Patients were randomized to	between easily observable baseline characteristics/demographics and	gender, weight, the length of time they had previously taken donepezil	V/Æ
al.,	donepezil 23mg/day or to continue	cognitive improvement in patients	or their functional impairment,	
2013	10mg/day.	treated with either donepezil 23	donepezil 23 mg/d over 10 mg/d	
	Sample Design: 1467 patients with	mg/d or 10 mg/d and to identify	produced cognitive gains (p=-0.011	
	probable AD, taking donepezil 10	factors that might have an impact	and p>0.05).	
	mg/d for >= three months, and not	on response.		
	taking daily doses of <=20 mg of memantine for >= 3 months before			
	screening.			
Wallir	Study Design: Prospective clinical	To investigate the outcome of	Three years of donepezil medication	R/+;
et	trial. Patients began with 5 mg/day	continuous donepezil long-term	resulted in a favorable behavioral	V/+
al.,	donepezil and increased to 10	treatment on patients with	and cognitive results (p<0.001).	
2006	mg/day after 4-8 weeks.	Alzheimer' disease in the typical		
	Sample Design: 430 patients with	clinical settings.		
	AD, >= 40, residing at home, have a			
	caregiver, and not having another AChEI.			
Win-	Study Design: 6-month	To ascertain the effectiveness of	Overall, the study shows that	R/+;
blad	double-blind, controlled study.	donepezil in patients with severe	donepezil is a successful and	V/Æ
et	Patients were assigned oral	Alzheimer's disease, by focusing	well-tolerated treatment. Donepezil	
al.,	donepezil (5mg/day for 30 days	primarily on cognition and activities	maintains function and improves	
2006	then up to 10mg/day) or matched	of daily living.	cognition in nursing home residents	
	placebo.		with severe Alzheimer's disease	
	Sample Design: 248 patients with possible AD, >= 50 years old, and		(p=0.008).	
	able to walk unassisted or with			
	assistance.			

AD = Alzheimer's diseaseADL = Activities of daily living ChEI = Cholinesterase inhibitors MCI = Mild cognitive impairment MMSE = Mini-Mental Stare Examination R = RelevanceV = Validity

3.6 | Rivastigmine Cognitive Outcomes

Among the included studies, only six studies examined the effectiveness of rivastigmine in delaying the worsening of cognitive functions associated with the disease as shown in Table 7. Karaman et al. (2004) showed patients who received rivastigmine 6-12 mg/day demonstrated significantly improved (p<0.001) cognitive performance. Karaman and his team (2004), Feldman & Lane (2007), and Grossberg et al. (2004) discovered long-term rivastigmine therapy looked to be well tolerated and significantly reduced cognitive and functional symptoms of AD patients compared to no treatment (p<0.001, p<0.05, respectively). Almkvist et al. (2004) and Cecri et al. (2007) noted rivastigmine therapy stabilized cognition with little improvement in cognitive skills (p<0.05, p>0.01, respectively). Almkvist (2004) also highlighted patients undergoet al. ing rivastigmine treatment for Alzheimer's disease showed more improvement (p<0.05) over time with a larger dose of 10.5-12 mg/day than with a lower dose of 3-6 mg/day. Feldman et al. (2007) found that over 4 years, rivastigmine had little to no significant impact (p=0.726) on cognitive function or on the rate at which AD progressed. Overall, rivastigmine treatment can significantly enhance cognitive performance and alleviate AD symptoms demonstrating tolerability and continuous benefits in managing cognitive decline.

Table 8. Studies Examinin	y the Effectiveness of	f Galantamine on Cognition Part A
	S the Encethericss of	

Baak-	Study Design: 6-month	To examine the potential for	Patients with AD show a decrease in	R/+;
man	double-blind, randomized	determining long-term treatment	theta and delta waves following a	V/+
et	cross-over study. The challenge	response as well as the immediate	single administration of	
al., 2022	phase, 1 dose of 16mg galantamine. In the treatment phase, open-label galantamine. Sample Design: 50 participants with AD, never used of ChEIs, and no history of psychiatric illnesses.	pharmacodynamic (PD) effects of a single dose of galantamine on the activity of the central nervous system (CNS) in patients with mild to severe Alzheimer's disease.	galantamine 16 mg leading to lower cognitive functions (p=0.0001).	
Bro- daty et al., 2006	Study Design: 6-month prospective study. Participants were given galantamine. Sample Design: 345 patients with mild to moderate AD related dementia, currently reside at home, have a caregiver, and speak enough English.	To collect detailed information about galantamine's use in treating Alzheimer's disease under realistic circumstances.	Most galantamine-treated participants who finished the trial kept their cognition, behavior, or function stable. At six months, most of the individuals had an improvement in cognition compared to baseline.	R/+; V/Æ
Burns et al., 2009	Study Design: 6-month, double-blind, randomized trial. Patients randomly received 24mg/day galantamine or placebo. Sample Design: 407 ambulatory patients with probable AD, aged 40-95, have a history of cognitive decline for >= 6 months, good vision and hearing.	To assess the efficacy of galantamine in patients with severe AD.	Galantamine significantly improved cognitive functioning, especially in the domains of practice, memory, and visuospatial ability (p=0.006, p=0.002, p=0.076, respectively).	R/+; V/+

Table 9. Part B

Caran	neatudy Design: 12-week prospective,	To assess the impact of galantamine	After 12 weeks of treatment with	R/+
et al., 2004	open-label, study. Galantamine started at 4mg for 4 weeks, 8 mg/day for 4 weeks, then 12 mg/day for 4 weeks. Sample Design: 33 patients with probable AD, age 56-87 years, high education level, reside with or get visits from a caregiver, no blood circulatory problems, no AChEl >= 60 days prior to inclusion.	on the cognitive abilities of individuals with mild to severe Alzheimer's disease (AD) on a computerized neuropsychological test battery (CNTB).	galantamine at a dose of 16 to 24 mg/day, individuals suffering from mild to moderate Alzheimer's disease did not improve significantly (p=0.003) in cognition scores.	V/Æ
Gaudi et al., 2011	igStudy Design: 6-week, double-blind study. Patients received placebo, galantamine 8mg/day, or	To evaluate the effects of galantamine withdrawal and compare this with uninterrupted therapy. To compare the effects of discontinuation of galantamine therapy after 3- 5 months with those of continuing it for an additional 6 weeks.	Galantamine treatment have shown cognitive gains from galantamine treatment for up to 5 months (p=0.001). Patients with advanced moderate AD may benefit from continuing their galantamine.	R/+; V/Æ
Gorus et al., 2007	 S Study Design: 22-weeks open-label prospective trial. Galantamine was administered at 2x4 mg/day, then 2x12 mg/day max. Sample Design: 41 mild-severe AD outpatients, with probable AD. 	To investigate the impact of galantamine on reaction time, selective attention, alternating attention, errors, and interindividual and intraindividual variability in seniors with moderate to severe Alzheimer's disease.	There was an improvement in memory and language (p=0.695, p=0.012, respectively) after 22 weeks. There was also a decrease in the number of mistakes.	R/+; V/+

Table 10. Part C

Lykett	sostudy Design: 12 month, open-label	To assess the long-term safety,	Patients using galantamine	R/+;
et al., 2004	extension of a previous 5-month, double-blind, trial. Patients increased to a 24-mg galantamine over two weeks for an additional 12 months. Sample Design: 699 patients with probable AD, score of >= 18 on AD Cognition Assessment Scale, and	effectiveness, and tolerance of galantamine 24 mg/day in the treatment of Alzheimer's disease.	consistently demonstrated persistent cognitive improvements on cognition part (p<0.001).	V/+
Mintz	have a caregiver. erStudy Design: 5-month double-blind	To assess the effects of	Patients treated with galantamine 16	R/+;
&	study. Participants received placebo,	galantamine in patients with AD	mg/day and 24 mg/day experienced	V/+
Ker-	galantamine 8 mg/day, 16 mg/day, or	who had previously been	statistically significant improvements	
shaw,	24 mg/day.	exposed to AChEIs to those	in cognitive performance when	
2003	Sample Design: 975 patients with probable AD, and discontinued AChEI for >= 60 days prior to study admission.	patients with AD who had not previously been exposed.	compared to placebo (p=0.003, p<0.001, respectively).	
Pirt-	Study Design: 36-month open-label	To assess long-term	In individuals with mild-to-moderate	R/+;
tila	extension study. Patients took 12mg	effectiveness and safety of	Alzheimer's disease, 12 mg of	V/Æ
et	galantamine twice/day for up to 24	galantamine in individuals with	galantamine twice day for 36 months	
al.,	months.	mild-to-moderate Alzheimer's	is efficacious, safe, and well	
2004	Sample Design: 491 patients with probable AD had galantamine <= 12	disease	tolerated. Cognitive scores improved significantly (p<0.001).	
	months, had a history cognitive			
	deterioration, and have a caregiver.			

Table 11. art C

etclinical trial. Patients began with galantamine 8mg/day then 4mg/dayeffectiveness of galantamine in community-dwelling persons with mildgalantamine was typically well tolerated and safe. During the 12-monthV/+2014increments for 2 weeks until 16mg/day. Sample Design: 75 patients had a possible or probable AD, >= 45 years old, and not taking anticholinergic medications.community-dwelling persons with mild Alzheimer's disease.cognition, behavior, and daily living skills (p<0.05).V/+SongStudy Design: 52-week open-labeled, patients were given 8 mg ofTo examine at the impact of galantamine on cognitive subdomains in Mg/day at 4-week intervals. Sample Design: 66 patients who had probable AD, a history of progressive cognitive decline, and a caregiver.To examine at the impact of galantamine on cognitive subdomains in Alzheimer's disease (AD).Galantamine is particularly useful in areas (p<0.001) and attention (p=0.036)R/+;	Richa	rzStudy Design: A 36-month prospective,	To assess long-term	During the three years of observation,	R/+;
 2014 increments for 2 weeks until 16mg/day. Sample Design: 75 patients had a possible or probable AD, >= 45 years old, and not taking anticholinergic medications. Song Study Design: 52-week open-labeled, et clinical study. During the 1st 4 weeks, al., patients were given 8 mg of 2014 galantamine/day, then a max of 24 mg/day at 4-week intervals. Sample Design: 66 patients who had probable AD, a history of progressive Community-dwelling persons with mild Community-dwelling persons with mild Community-dwelling persons with mild Community-dwelling persons with mild Alzheimer's disease. Community-dwelling persons with mild Alzheimer's disease (p<0.05). Galantamine is particularly useful in boosting memory and language cognition areas (p<0.001) and attention (p=0.036) V/+ 		8			V/+
Sample Design: 75 patients had a possible or probable AD, >= 45 years old, and not taking anticholinergic medications.persons with mild Alzheimer's disease.cognition, behavior, and daily living skills (p<0.05).SongStudy Design: 52-week open-labeled, clinical study. During the 1st 4 weeks, al., patients were given 8 mg of mg/day at 4-week intervals.To examine at the impact of galantamine on cognitive subdomains in Alzheimer's diseaseGalantamine is particularly useful in areas (p<0.001) and attention (p=0.036)	al.,		•	and safe. During the 12-month	
or probable AD, >= 45 years old, and not taking anticholinergic medications.Alzheimer's disease.(p<0.05).SongStudy Design: 52-week open-labeled, clinical study. During the 1st 4 weeks, al., patients were given 8 mg ofTo examine at the impact of galantamine on cognitiveGalantamine is particularly useful in boosting memory and language cognition areas (p<0.001) and attention (p=0.036)R/+;2014galantamine/day, then a max of 24 mg/day at 4-week intervals. Sample Design: 66 patients who had probable AD, a history of progressiveAlzheimer's disease (AD).(AD).	2014	increments for 2 weeks until 16mg/day.	community-dwelling	treatment, improvements were made in	
taking anticholinergic medications.To examine at the impact of galantamineGalantamine is particularly useful in boosting memory and language cognition areas (p<0.001) and attention (p=0.036)R/+;2014galantamine/day, then a max of 24 mg/day at 4-week intervals. Sample Design: 66 patients who had probable AD, a history of progressiveTo examine at the impact of galantamine on cognitive Alzheimer's disease (AD).Galantamine is particularly useful in boosting memory and language cognition areas (p<0.001) and attention (p=0.036)		Sample Design: 75 patients had a possible	persons with mild	cognition, behavior, and daily living skills	
SongStudy Design: 52-week open-labeled, clinical study. During the 1st 4 weeks, patients were given 8 mg ofTo examine at the impact of galantamine on cognitive subdomains in Alzheimer's disease Sample Design: 66 patients who had probable AD, a history of progressiveTo examine at the impact of galantamine on cognitive subdomains in Alzheimer's disease (AD).Galantamine is particularly useful in boosting memory and language cognition areas (p<0.001) and attention (p=0.036)R/+; V/+2014galantamine/day, then a max of 24 mg/day at 4-week intervals. Sample Design: 66 patients who had probable AD, a history of progressiveTo examine at the impact of galantamine on cognitive subdomains in Alzheimer's disease (AD).Galantamine is particularly useful in boosting memory and language cognition areas (p<0.001) and attention (p=0.036)		or probable AD, >= 45 years old, and not	Alzheimer's disease.	(p<0.05).	
etclinical study. During the 1st 4 weeks, patients were given 8 mg ofimpact of galantamine on cognitiveboosting memory and language cognitionV/+al.,patients were given 8 mg ofon cognitiveareas (p<0.001) and attention (p=0.036)		taking anticholinergic medications.			
al.,patients were given 8 mg ofon cognitiveareas (p<0.001) and attention (p=0.036)2014galantamine/day, then a max of 24 mg/day at 4-week intervals.subdomains inAlzheimer's disease probable AD, a history of progressiveAlzheimer's disease	Song	Study Design: 52-week open-labeled,	To examine at the	Galantamine is particularly useful in	R/+;
2014galantamine/day, then a max of 24 mg/day at 4-week intervals.subdomains inSample Design: 66 patients who had probable AD, a history of progressive(AD).	et	clinical study. During the 1st 4 weeks,	impact of galantamine	boosting memory and language cognition	V/+
mg/day at 4-week intervals.Alzheimer's diseaseSample Design: 66 patients who had probable AD, a history of progressive(AD).	al.,	patients were given 8 mg of	on cognitive	areas (p<0.001) and attention (p=0.036)	
Sample Design: 66 patients who had (AD). probable AD, a history of progressive	2014	galantamine/day, then a max of 24	subdomains in		
probable AD, a history of progressive		mg/day at 4-week intervals.	Alzheimer's disease		
		Sample Design: 66 patients who had	(AD).		
cognitive decline, and a caregiver.		probable AD, a history of progressive			
		cognitive decline, and a caregiver.			
		-	ing		
AD = Alzheimer's diseaseADL = Activities of daily living	ChEL-	Chalinesterase inhibitors			

ChEI = Cholinesterase inhibitors

MCI = Mild cognitive impairment

MMSE = Mini-Mental Stare Examination

R = RelevanceV = Validity

Table 12. Studies Examining the Effectiveness of Rivastigmine on Cognition Part A

	0			
Alml	xvi s tudy Design: 12-month study.	To explore the effects of a 12-month	When rivastigmine-treated AD	R/+;
et	Every 2 weeks, the dosage was	rivastigmine medication on overall	patients were compared with	V/+
al.,	increased by 1.5 mg, low dose was	cognitive performance, visuospatial	untreated AD and MCI patients over	
2004	3-6mg/day and high dose was	ability, attention, and memory in	time, a general pattern of stabilized	
	10.5-12 mg/day.	mild AD patients. The results were	cognitive performance was	
	Sample Design: 54 participants with	compared with groups of matched	observed. Higher dose of	
	probable AD. 1st control had AD	untreated AD patients as well as	rivastigmine showed more	
	patients from the past. 2nd control	individuals with MCI.	improvements than a lower dose	
	group had MCI diagnosis.		(p<0.05).	
Cecr	i Study Design: Rivastigmine 3	To look for alterations in cerebral	Rivastigmine therapy didn't	R/+;
et	mg/day was administered for the	perfusion, assessing cognition, and	significantly modify brain perfusion,	V/Æ
al.,	first four weeks of therapy before	the effects of rivastigmine on single	except in the inferior frontal lobe.	
2007	being raised to 6 mg/day. Sample	photon emission computed	Cognitive function was stable or	
	Design: 15 patients, ages 64-95,	tomography prior to and following	improved a little throughout the	
	had probable mild to severe AD.	treatment.	treatment (p<0.01).	
Feld	Study Design: Double-blind,	To assess the effect of rivastigmine	Over a 4-year period, rivastigmine	R/+;
man	randomized clinical trial. Patients	in patients with mild cognitive	had little to no significant impact	V/+
et	were randomized to rivastigmine	impairment (MCI) on the time to	(p=0.726) on the rate at which AD	
al.,	(3–12 mg/day) or placebo. Sample	clinical diagnosis of Alzheimer's	progressed or on cognitive function.	
2007		disease (AD) and the rate of		
	depression, and not having severe	cognitive decline.		
		-		

Table 12 Dart P

medical condition.

Feld-	Study Design: 26 week, randomized	To assess the effectiveness and	Rivastigmine was found to	R/+
man	double blind study. Patients were	safety of rapidly titrated	significantly improve cognitive,	V/+
&	given rivastigmine 2-12 mg/day 2 or	rivastigmine administered twice	functional, and overall performance	•/ ·
Lane,	3 times/day or placebo.	or three times daily in patients	in AD patients when taken twice or	
2007	Sample Design: 678 patients, >= 50	with mild to moderate	three times per day (p<0.05).	
2007	years old, had probable AD, had a	Alzheimer's disease (AD).	tillee tilles per day (p<0.05).	
	responsible caregiver, and have no	Alzheimer s'uisease (AD).		
	concurrent conditions.			
Kara-	Study Design: 12-month randomized	To analyze the long-term	Patients who took rivastigmine for 1	R/+;
man	study. Patients were randomly	outcome of rivastigmine	year saw significant improvements	V/Æ
et	assigned to placebo or rivastigmine	treatment and to determine the	compared placebo (p<0.001). By 52	V/AL
	treatment (tablet twice/day, dose	efficacy of rivastigmine in	weeks, patients using rivastigmine	
al., 2004				
2004	increased by 1.5mg every 2 weeks).	patients with advanced moderate AD.	6–12 mg/day significantly improved	
	Sample Design: 44 ambulatory or	moderate AD.	cognitive performance compared to	
	ambulatory-aided patients, had		those taking a placebo (p<0.001).	
	probable AD, and sufficient vision			
C	and hearing.	To increasion to colorate an		D/.
	Study Design: For 26 weeks, patients	To investigate whether	Rivastigmine was safe and improved	R/+;
berg,	were randomly assigned to	rivastigmine remained	cognitive function in individuals with	V/Æ
2004	rivastigmine 1mg-6mg bid or	therapeutically beneficial after	AD for up to 2 years, compared to	
	placebo.	up to 2 years of therapy in	placebo (p<0.05).	
	Sample Design: Patients with	individuals with probable		
	probable mild to moderate AD, and	Alzheimer's disease.		
	had a MMSE score 10-26.			

AD = Alzheimer's diseaseADL = Activities of daily living

- ChEI = Cholinesterase inhibitors
- MCI = Mild cognitive impairment
- MMSE = Mini-Mental Stare Examination
- R = RelevanceV = Validity

3.7 | Acetylcholinesterase Inhibitors Comparison on Cognitive Outcomes

Among the included studies, 12 studies compared the effectiveness of different AChE inhibitors (donepezil, galantamine, and rivastigmine) in delaying the worsening of cognitive functions associated with the disease as shown in Table 8. Wilcock et al. (2003) favor galantamine in the early and longterm management of mild-to-moderate Alzheimer's disease over donepezil, citing a significant betweengroup difference (p<=0.05). The authors emphasized the AChE inhibitors' efficacy in maintaining cognition. In contrast, Jones et al. (2004)favor donepezil, highlighting the drug's substantial advantages in cognition (p<0.05) as compared to galantamine in week 12. Both medications were well tolerated, but the donepezil group reported fewer gastrointestinal adverse events than the galantamine group. Aguglia et al. (2004) highlighted cognitive functions improved significantly in the rivastigmine group (p<0.05) and galantamine groups (p<0.05). Bullock et al. (2005) discovered rivastigmine showed superior efficacy over donepezil on cognition (p=0.007). Meanwhile, Xu et al. (2021) and Lopez-Posa et al. (2005) noted there were no significant differences (p>0.05) among different AChE inhibitors' effects on cognition.

Olazran et al. (2005) found patients receiving 5-10mg of donepezil or 6-12mg of rivastigmine

in addition to a cognitive-motor intervention, further cognitive advantages were seen in months one and six (p=0.05, p=0.95, respectively). Loewenstein et al. (2004) showed improvement in facename memory (p<0.001) and orientation (p=0.006), (2005) noted enhancements in Crowell et al. recognition memory (p<0.05), while Rozzini et al. (2006) discovered improvements in episodic memory (p<0.01) and abstract reasoning (p<0.02) in mildly impaired Alzheimer's disease patients taking an AChE inhibitor and neuropsychological training. Calabria et al. (2008) added patients' cognition after receiving AChE inhibitors improved after three months of therapy (p<0.001) and then dropped at month 21 (p=0.006). Like Calabria et al., Connelly et al. (2004) noted statistically significant improvements in cognition (p<0.0005) and activities of daily living (p=0.025) after 3 months. Wattmo et al. (2012) demonstrated patients who improved or remained stable in cognitive functions had superior cognition states, were younger, and took fewer antidepressants (p<0.001). Sun et al. (2007) highlighted while gender (p=0.07) and types of medicine (p=0.62) were not significant factors, age was the only significant associated factor with treatment duration (p=0.0006). While different opinions exist regarding the preferred choice of AChEI in the management of AD, most studies agree on the efficacy of AChEI in maintaining cognitive function.

4 | QUALITY/RISK ASSESSMENT

Each article's quality/risk assessment demonstrated an overall positive result in the relevant questions. This systematic review used 45 studies in total. Mixed validity was observed, with primarily positive or neutral results. All the articles that were part of this review were adequately addressed because no article received a negative validity rating. Twentyfive of those studies had a "+" rating, which indicated that the articles addressed inclusion/exclusion, bias, generalizability, and data collection and analysis (Academy of Nutrition and Dietetics, 2016). Twenty studies had a rating of "", which indicated the articles were neither exceptionally strong nor exceptionally weak (Academy of Nutrition and Dietetics, 2016). Overall, all articles were considered relevant, and some showed positive validity while others showed neutral validity.

Table 14. Studies Examining the Effectiveness of Different AChEI on Cognition Part A

Agugl	iætudy Design: 6-month comparison	To investigate the effects of	Cognition improved in the	R/+;
et al.,	research. Patients were given rivastigmine 1.5 mg twice/day then 3	donepezil, rivastigmine, and galantamine, which are used to	rivastigmine and galantamine groups with significant differences between	V/Æ
2004	mg, or donepezil 5 mg once/day then 10 mg, or galantamine 4 mg twice/day then 8 mg. Sample Design: 242 participants with AD for at least 6 months and not taking AChEI.	treat Alzheimer's disease, in a real-world context.	both but decreased in the donepezil (p<0.05, p<0.05, respectively)	
Bul-	Study Design: 24-month	To assess over a 2-year period	For cognitive functioning, neither	R/+;
lock	double-blind, randomized controlled	the effectiveness and tolerability	rivastigmine nor donepezil	V/Æ
et	trial. Participants were randomly	of cholinesterase inhibitor	demonstrated a comparative	
al., 2005	assigned to receive donepezil 5-10 mg/day or rivastigmine 3–12 mg/day.	therapy in individuals with moderate to moderately severe Alzheimer's disease.	advantage. Rivastigmine medication may be more effective for specific patient subpopulations (p=0.007).	
	Sample Design: 994 outpatients, 50-85 years old, had AD or probable AD, have a caregiver once/ day.			
Cal-	Study Design: 21-months. Patients	To investigate cognitive and	The findings demonstrate that	R/+;
abria	assigned to 5 or 10 mg/day	functional results in 427 AD	patients' cognition improved after 3	V/Æ
et	donepezil- therapy or 3 to 12 mg/day	patients during a 21-month	months (p<0.001), remained steady	
al.,	rivastigmine.	period.	for 15 months, and then dropped at	
2009	Sample Design: 427 patients with		month 21 (p=0.006).	
	probable mild-to-moderate AD.			

Table 15. Part B

Table 1	5. Part B			
Con-	Study Design: 3-year cohort study.	To study the potential that response	Although neither of the initial	R/+;
nelly	First 3 months, participants took	to cholinesterase inhibitor	changes were statistically significant	V/+
et	donepezil 5 mg/day, rivastigmine 6	medication might be predicted by	at 6 months, there was a	
al.,	mg/day, or galantamine 16 mg/day.	easily measured factors that change	statistically significant improvement	
2005	Maintained dosage if improved, if	because of treatment, such as	in cognition (p<0.0005) and	
	not, greatest tolerable dosage was	measures of function and attention.	activities of daily living (p = 0.025)	
	given.		after 3 months.	
	Sample Design: 160 patients with			
	probable AD with a score of 11-26			
	on the MMSE, and no			
	cerebrovascular illness.			-
	Study Design: 2-year trial. Patients	To investigate the effect of	The principal advantage of ChEI	R/+;
ell	took donepezil or rivastigmine.	cholinesterase inhibitor drugs on	therapy on memory appears to be	V/Æ
et	Patients who have not taken any	recognition memory function in	enhancing retention of new	
al.,	ChEI before were used as a	patients with mild to moderate	material (p<0.05) in memory in mild	
2006	comparison group.	Alzheimer's disease	to severe Alzheimer's disease	
	Sample Design: 28 patients with a		patients.	
	probable AD, memory issues, and			
	had been taking AChEI for >= 1 month.			
lonor	Study Design: 12-week, randomized	To compare the ease of use and	Assessments of cognition and ADL	R/+;
et	clinical trial. Patients were	tolerability of donepezil and	demonstrated substantial	ку <i>т</i> , V/+
al.,	randomly assigned to 5mg/day	galantamine in the treatment of	advantages for donepezil as	V/T
2004	donepezil then 10 mg/day or 4mg	Alzheimer's disease (AD) and	compared to galantamine (p<0.05)	
2004	twice/day galantamine then 8 mg	investigate the effects of both	in week 12. Donepezil group	
	twice/day then 12 mg twice/day.	treatments on cognition and	reported fewer GI adverse events	
	Sample Design: 120 patients with	activities of daily living (ADL).	than galantamine group.	
	possible AD, >= 50 years old, and		than Salantanine Sroup.	
	have a caregiver.			

Table 16. Part C

Loewe et al., 2004	cn 6tuely Design: Random selection to Cognitive Rehabilitation or Mental Stimulation training, with different ChEI dosage in both groups. All participants attended training sessions twice/week. Sample Design: 44 participants with possible AD and a severe increasing deficit in memory.	To assess the effectiveness of a novel cognitive rehabilitation program on memory and functional performance in mildly impaired Alzheimer's disease patients taking a cholinesterase inhibitor.	Improvements in face-name connection memory (p<0.001), and orientation (p=0.001), and particular functional activities were observed after the intervention and during the 3-month follow-up.	R/+; V/Æ
Lopez- Pousa et al. <i>,</i> 2005	Study Design: Open-label,	To compare the effectiveness of acetylcholinesterase inhibitors to a previous sample of individuals with Alzheimer's disease who were not treated with acetylcholinesterase inhibitors.	There were no significant variations in effectiveness between donepezil, galantamine, and rivastigmine in the investigation (p>0.05). At 6 months, patients treated with ChEIs show more improvement than untreated individuals.	R/+; V/+
Olazar et al., 2004	 ástudy Design: 1-year program. Patients were randomized to receive psychosocial assistance along with cognitive-motor intervention or only psychosocial support. Sample Design: 84 patients with probable AD and have been taking donepezil or rivastigmine for > 1 month. 	To evaluate the effectiveness of a cognitive-motor program in patients with early Alzheimer disease (AD) who are treated with a cholinesterase inhibitor (ChEI).	While patients in the control group had dramatically worsened by month 6, cognitive advantages were seen in those in the cognitive motor intervention group in month 1 (p=0.05) and month 6 (p=0.95).	R/+; V/Æ

5 | DISCUSSION

The systematic review aimed to assess the effectiveness of acetylcholinesterase inhibitors (AChEIs) including donepezil, galantamine, and rivastigmine in delaying the worsening of cognitive function in patients with Alzheimer's disease. The review addressed three primary objectives: Assessing the overall efficacy of AChEIs in improving cognitive functions, comparing cognitive benefits across different types of AChEIs, and identifying gaps in the current literature to guide future research. The findings from the 45 selected articles give important insights into the efficacy and benefits of AChEIs in cognitive improvement.

The review found constant evidence AChE inhibitors improved cognitive outcomes in Alzheimer's disease patients (Black et al. 2007, Boada-Rovira et al. 2004, Brodaty et al. 2006, Burns et al. 2009, Feldman et al. 2003, Feldman al. 2004, Han et al. 2016, Homma et al. 2008, Howard et al. 2012, Johannsen et al. 2006, Karaman et al. 2004, Lyketsos et al. 2004, Mintzer & Kershaw 2002, Molinuevo et al. 2009, Pirtilla et al. 2003, Richarz et al. 2014, Sabbagh et al. 2003, Wallin et al. 2006, Winblad et al. 2006). The results of this review match prior research that suggests AChEIs play an important role in improving cognitive decline, particularly in areas such as global cognitive function, memory, decision-making, and attention (Boada-Rovira et al. 2004, Bullock et al. 2005, Burns et al. 2009, Crowell et al. 2005, Feldman et al. 2005, Loewenstein et al. 2004, Rozzini et al. 2006). Studies also demonstrated increasing the AChE inhibitors dose can potentially lead to greater inhibition of the enzyme acetylcholinesterase which can have a positive impact on cognition in some patients with Alzheimer's disease (AD), especially those with early-stage AD (Almkvist et al. 2004,

& Lane 2007, Gaudig et al. 2011, Grossberg et

Table 17. Part D

Rozzir et al.,	niStudy Design: 1-year longitudinal, retrospective study. Patients were distributed to Neuropsychological	To assess the effectiveness of a neuropsychological training in patients with MCI who receive	The group who received ChEIs and neuropsychological training increased their cognitive abilities,	R/+ V/+
2007		treatment with cholinesterase inhibitors (ChEIs) to individuals with MCI who are not treated with ChEIs.	especially their memory (p<0.01) and abstract reasoning (p<0.02).	
Sun et al., 2008	Study Design: Donepezil was first introduced, followed by rivastigmine, then galantamine	To assess the duration of acetylcholinesterase inhibitor, use as well as the patients' cognition stability.	AD was highest in ages 70-80 years old with the most cognitive impairment (p=0.0006). This was the age which changes or worsens cognitive ability. Gender (p=0.07) and types of medicine (p=0.62) were not significant factors affecting cognition.	R/+; V/Æ
Wilco et al., 2003	c&tudy Design: 52-week randomized, rater-blinded study. Patients were randomized to galantamine 8mg	To compare the long-term efficacy and safety of galantamine 24 mg/ day and donepezil 10 mg/day in patients with Alzheimer's disease.	Galantamine is better for early and long-term management of individuals with mild-to-moderate AD due to its great efficacy in maintaining cognition when compared to donepezil (p<=0.05).	R/+; V/+
et al. <i>,</i>	 Notudy Design: 3-year, non-randomized research. Patients were given donepezil, rivastigmine, or galantamine. Sample Design: 784 patients aged >40 with a diagnosis of dementia and possible AD, have been living at home, and have a caregiver. 	To determine the socio-demographic and clinical parameters that influence functional and cognitive performance after 6 months of ChEI treatment.	After 6 months of ChEI treatment, patients improved or did not really change in ADL and physical self-care. Patients who improved or remained stable had superior cognitive state (p<0.001).	R/+; V/+
Xu et al., 2021	Study Design: A longitudinal cohort study. Patients received 7.5 mg/day donepezil, or 9mg rivastigmine, or 16 mg galantamine. Sample Design: 39,196 patients, diagnosed with Alzheimer dementia or mixed Alzheimer dementia, no ChEI treatment of more than 3 months.	To examine if cholinesterase inhibitors (ChEIs) are linked to slower cognitive loss in Alzheimer's disease and a lower risk of severe dementia or mortality.	ChEIs have a correlation with moderate cognitive improvements that remain over time. There were no significant differences among different ChEIs effects on cognition (p>0.05).	R/+; V/+

AD = Alzheimer's diseaseADL = Activities of daily living ChEI = Cholinesterase inhibitors MCI = Mild cognitive impairment MMSE = Mini-Mental Stare Examination

R = RelevanceV = Validity

2633

Han et al. 2016, Homma et al. 2008, Mintzer & Kershaw 2002, Pirtilla et al. 2003, Richarz et al. 2014, Sabbagh et al. 2003). Yet, while higher doses can further improve cognition for some patients with AD, these higher doses can also increase the risk of adverse effects such as nausea, vomiting, diarrhea, headaches, and muscle cramps (Bullock et al 2005, Feldman & Lane 2007, Jones et al 2004, Pirtilla et al 2004). AChE inhibitors have also been shown to be well-tolerated and effective in improving cognitive function for several months to years (Baakman et al. 2022, Feldman & Lane 2007, Grossberg et al. 2004, Karaman et al. 2004, Lykettsos et al. 2004, Pirttila et al. 2004, Richarz et al. 2014, Wallin et al. 2006, Wilcock et al. 2003). AChE inhibitors are effective in enhancing cognitive outcomes; however, it should be noted that higher doses may lead to increased inhibition of AChE, which could exacerbate side effects.

The ability of donepezil to increase memory, slow down the onset of cognitive decline, and improve general cognitive performance is well documented in the literature (Black et al. 2007, Boada-Rovira et al. 2004, Feldman et al. 2003, Feldman et al. 2005, Han et al. 2016, Homma et al. 2008, Howard et al. 2012, Johannsen et al. 2006, Molinuevo et al. 2009, Sabbagh et al. 2003, Wallin et al. 2006, Winblad et al. 2006). There is evidence that galantamine is beneficial in enhancing cognitive abilities, specifically in the domains of memory and attention (Brodaty et al. 2006, Burns et al. 2009, Gaudig et al. 2011, Gorus et al. 2007, Lyketsos et al. 2004, Pirtilla et al. 2003, Richarz et al. 2014, Song et al. 2014). With an emphasis on executive function, rivastigmine has demonstrated effectiveness in enhancing cognitive abilities (Almkvist et al. 2004, Cecri et al. 2007, Feldman & Lane 2007, Grossberg et al. 2004, Karaman et al. 2004). The complexity of identifying the best AChEI is increased by the fact different studies in the systematic review identified one AChEI as being more effective than Thus, it is unclear from the available another. data which AChEI offers the greatest significant cognitive advantages. These variations emphasize the significance of adapting treatment options to certain patient demands and cognitive problems. Despite these differences, a recurring theme appears that all AChEIs (donepezil, galantamine, and rivastigmine) are useful in improving cognitive

abilities. Variations in acetylcholinesterase inhibitor effectiveness might be attributed to variability in the selected studies, patient groups, and outcome measures. Most included studies revolved around shortterm and medium-term treatment periods, necessitating additional research into the long-term cognitive effects of AChEIs. Furthermore, the findings emphasize the necessity of individualized therapy methods and subjects for future study to better understand the potential of AChEIs in cognitive decline management in patients with Alzheimer's disease.

Acetylcholinesterase inhibitors (AChEIs) are recommended for the treatment of Alzheimer's disease by the American Alzheimer's Association (AAA). Cholinesterase inhibitors are given to address problems with language, memory, reasoning, judgment, and other cognitive functions. These medications inhibit acetylcholine, a neurotransmitter crucial to memory and learning, from breaking down (American Alzheimer's Association, 2024). AChEIs also facilitate nerve-to-nerve com-The three cholinesterase inhibitors munication. most frequently prescribed are donepezil (Aricept), rivastigmine (Exelon), and galantamine (Raza-According to the American Alzheimer's dvne). Association (2024), galantamine and rivastigmine are recommended for mild to moderate dementia, whereas donepezil is for mild to severe dementia caused by Alzheimer's. While generally welltolerated, adverse effects are occasionally reported to include nausea, vomiting, an increase in the frequency of bowel movements, and loss of appetite (American Alzheimer's Association, 2024).

Quality Assessment/Bias Assessment

Based on the quality assessment conducted using the Academy of Nutrition and Dietetics Evidence Analysis Library's grading table (Academy of Nutrition and Dietetics, 2020), the systematic review is classified as Grade II - Fair. This was based on the quality of the studies, appropriateness of inclusion criteria for studies, adequacy of data extraction methods, and consistency of findings included in the review. Most of the studies received a rating of "+", indicating the articles addressed inclusion/exclusion, bias, generalizability, and data collection and analysis based on the Quality Criteria Checklist for primary research (Academy of Nutrition and Dietetics, 2016). Some studies had small sample sizes, studies

with fewer than 50 participants, which could have potentially impacted the generalizability and robustness of the findings. Additionally, there were some nonsignificant results, particularly in cognition outcomes. Despite these limitations, high methodological qualities, consistency in the findings, and high levels of statistical significance were observed in the included studies. The strengths which increased the reliability and validity of the review, along with the minor limitations contributed to the fair quality rating assigned.

Strengths/Limitations

By including a diverse range of studies, the review provided a comprehensive appraisal of the impact of acetylcholinesterase inhibitors (AChEIs) on cognitive functions in Alzheimer's disease. An inclusive literature search strategy offers an in-depth examination of the available research studies. Other strengths also include the number of studies reviewed and the systematic approach of the review guided by the comprehensive PRISMA guidelines. Despite its strengths, this systematic review has some limitations. Its eligibility criteria had to be broader in terms of the publication date and restricted to English articles. Also, variability in participant characteristics and AD stages made it harder to draw consistent conclusions regarding the comparison between different AChEIs.

Application for Practitioner

Current research demonstrates AChEIs are effective in delaying the worsening of cognitive function in patients with Alzheimer's disease. Tailoring treatment plans according to each patient's unique profile becomes essential when considering the different cognitive benefits associated with different AChEIs. The use of AChEIs requires monitoring to minimize side effects, making sure the selected AChEI fits the patient's overall health. Given that AChEIs can improve a patient's general well-being and maintain cognitive improvement over time, incorporating them into long-term treatment can be considered.

6 | CONCLUSION

The effectiveness of acetylcholinesterase inhibitors (AChEIs) in delaying the worsening of cogni-

tive decline linked to Alzheimer's disease (AD) is thoroughly examined in this systematic review. The review, which was achieved by carefully examining 45 research articles, shows that AChEIs have a consistent beneficial effect on cognitive functions (Black et al. 2007, Boada-Rovira et al. 2004, Brodaty et al. 2006, Burns et al. 2009, Feldman et al. 2003, Feldman & Lane 2007, Gaudig et al. 2011, Grossberg et al. 2004, Han et al. 2016, Homma et al. 2008, Howard et al. 2012, Johannsen et al. 2006, Karaman et al. 2004, Lyketsos et al. 2004, Mintzer & Kershaw 2002, Molinuevo et al. 2009, Pirtilla et al. 2003, Richarz et al. 2014, Sabbagh 2003, Wallin et al. 2006, Winblad et al. et al. 2006). Although individual research revealed varying levels of effectiveness among different AChEIs, the body of evidence highlights the overall advantage of AChEIs in reducing cognitive deterioration in AD patients. The lack of a clear superior AChEI over the other highlights how crucial it is to customize treatment plans to the unique needs of each patient. Physicians should evaluate individual patient characteristics, disease extent, and the areas of cognition impacted.

Academy of Nutrition and Dietetics. (2016). Evidence analysis manual: Steps in the Academy Evidence Analysis Process. Evidence Analysis Library. 2016. https://www.andeal.org/vault/2440/web/files/ 2016_April_EA_Manual.pdf

Academy of Nutrition and Dietetics. (2020). Grade definitions and chart. EAL. https://www.andeal.org/ content.cfm?content_id=11

Aguglia, E., Onor, M. L., Saina, M., & Maso, E. (2004). An open-label, Comparative Study of Rivastigmine, Donepezil and galantamine in a real-world setting. Current Medical Research and Opinion, 20(11), 1747–1752. https://doi.org/10.1185/03 0079904x6273

Almkvist, O., Darreh-Shori, T., Stefanova, E., Spiegel, R., & Nordberg, A. (2004). Preserved cognitive function after 12 months of treatment with rivastigmine in mild alzheimer's disease in comparison with untreated AD and MCI patients. European Journal of Neurology, 11(4), 253–261. https://doi.or g/10.1046/j.1468-1331.2003.00757.x

Baakman, A. C., Gavan, C., van Doeselaar, L., de Kam, M., Broekhuizen, K., Bajenaru, O., Camps,

L., Swart, E. L., Kalisvaart, K., Schoonenboom, N., Lemstra, E., Scheltens, P., Cohen, A., van Gerven, J., & Groeneveld, G. J. (2022). Acute response to cholinergic challenge predicts long-term response to galantamine treatment in patients with alzheimer's disease. British Journal of Clinical Pharmacology, 88(6), 2814–2829. https://doi.org/10.111 1/bcp.15206

Black, S. E., Doody, R., Li, H., McRae, T., Jambor, K. M., Xu, Y., Sun, Y., Perdomo, C. A., & Richardson, S. (2007). Donepezil preserves cognition and global function in patients with severe alzheimer disease. Neurology, 69(5), 459–469. https://doi.org/10. 1212/01.wnl.0000266627.96040.5a

Boada-Rovira, M., Brodaty, H., Cras, P., Baloyannis, S., Emre, M., Zhang, R., & Bahra, R. (2004). Efficacy and safety of Donepezil in patients with alzheimer???s??disease. Drugs & amp; Aging, 21(1), 43–53. https://doi.org/10.2165/00002512-20042101 0-00004

Brodaty, H., Woodward, M., Boundy, K., Barnes, N., & Allen, G. (2006). A naturalistic study of galantamine for alzheimer's disease. CNS Drugs, 20(11), 935–943. https://doi.org/10.2165/00023210-200620 110-00006

Bullock, R., Touchon, J., Bergman, H., Gambina, G., He, Y., Rapatz, G., Nagel, J., & Lane, R. (2005). Rivastigmine and Donepezil treatment in moderate to moderately-severe alzheimer's disease over a 2year period. Current Medical Research and Opinion, 21(8), 1317–1327. https://doi.org/10.1185/030 079905x56565

Burns, A., Bernabei, R., Bullock, R., Jentoft, A. J., Frölich, L., Hock, C., Raivio, M., Triau, E., Vandewoude, M., Wimo, A., Came, E., Van Baelen, B., Hammond, G. L., van Oene, J. C., & Schwalen, S. (2009). Safety and efficacy of galantamine (reminyl) in severe alzheimer's disease (the Serad Study): A randomised, placebo-controlled, double-blind trial. The Lancet Neurology, 8(1), 39–47. https://doi.org/10.1016/s1474-4422(08)70261-8

Calabria, M., Geroldi, C., Lussignoli, G., Sabbatini, F., & Zanetti, O. (2009). Efficacy of acetyl-cholinesterase-inhibitor (ACHEI) treatment in alzheimer's disease: A 21-month follow-up "Real world" study. Archives of Gerontology and Geriatrics, 49(1). https://doi.org/10.1016/j.archger.2008. 07.006

Caramelli, P., Chaves, M. L. F., Engelhardt, E., Machado, J. C., Schultz, R. R., Vale, F. A. C., & Charchat-Fichman, H. (2004). Effects of galantamine on attention and memory in alzheimer's disease measured by computerized neuropsychological tests: Results of the Brazilian multi-center Galantamine Study (gal-bra-01). Arquivos de Neuro-Psiquiatria, 62(2b), 379–384. https://doi.org/10.159 0/s0004-282x2004000300001

Cerci, S. S., Tamam, Y., Kaya, H., Yildiz, M., & Arslan, S. (2007). Effect of rivastigmine on regional cerebral blood flow in alzheimer's disease. Advances in Therapy, 24(3), 611–621. https://doi.org/10.1007 /bf02848786

Connelly, P. J. (2005). Predicting the outcome of cholinesterase inhibitor treatment in alzheimer's disease. Journal of Neurology, Neurosurgery & amp; Psychiatry, 76(3), 320–324. https://doi.org/10.1136/jnnp.2004.043539

Crowell, T. A., Paramadevan, J., Abdullah, L., & Mullan, M. (2006). Beneficial effect of cholinesterase inhibitor medications on recognition memory performance in mild to moderate alzheimer's disease: Preliminary findings. Journal of Geriatric Psychiatry and Neurology, 19(1), 13–15. h ttps://doi.org/10.1177/0891988705284711

Doody, R. S., Ferris, S. H., Salloway, S., Sun, Y., Goldman, R., Watkins, W. E., Xu, Y., & Murthy, A. K. (2009). Donepezil treatment of patients with MCI: A 48-week randomized, placebo-controlled trial. Neurology, 72(18), 1555–1561. https://doi.or g/10.1212/01.wnl.0000344650.95823.03

Doody, Rachelle S, Corey-Bloom, J., Zhang, R., Li, H., Ieni, J., & Schindler, R. (2008). Safety and tolerability of Donepezil at doses up to 20 mg/day. Drugs & amp; Aging, 25(2), 163–174. https://doi.org/10.21 65/00002512-200825020-00008

Feldman, H. H., & Lane, R. (2007). Rivastigmine: A placebo controlled trial of twice daily and three times daily regimens in patients with alzheimer's disease. Journal of Neurology, Neurosurgery & amp; Amp; Psychiatry, 78(10), 1056– 1063. https://doi.org/10.1136/jnnp.2006.099424

Feldman, H. H., Ferris, S., Winblad, B., Sfikas, N.,

Mancione, L., He, Y., Tekin, S., Burns, A., Cummings, J., del Ser, T., Inzitari, D., Orgogozo, J.-M., Sauer, H., Scheltens, P., Scarpini, E., Herrmann, N., Farlow, M., Potkin, S., Charles, H. C., ... Lane, R. (2007). Effect of rivastigmine on delay to diagnosis of alzheimer's disease from mild cognitive impairment: The INDDEX study. The Lancet Neurology, 6(6), 501–512. https://doi.org/10.1016/s147 4-4422(07)70109-6

Feldman, H., Gauthier, S., Hecker, J., Vellas, B., Emir, B., Mastey, V., Subbiah, P., & Donepezil MSAD Study Investigators Group. (2003). Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe alzheimer's disease and the effect on caregiver burden. Journal of the American Geriatrics Society, 51(6), 737–744. https://doi.org/10.1046/j.1365-2389.2003.51260.x

Feldman, H., Gauthier, S., Hecker, J., Vellas, B., Xu, Y., Ieni, J. R., & Schwam, E. M. (2005). Efficacy and safety of donepezil in patients with more severe alzheimer's disease: A subgroup analysis from a randomized, placebo-controlled trial. International Journal of Geriatric Psychiatry, 20(6), 559–569. ht tps://doi.org/10.1002/gps.1325

Gaudig, M., Richarz, U., Han, J., Van Baelen, B., & Schauble, B. (2011). Effects of galantamine in alzheimers disease: Double-blind withdrawal studies evaluating sustained versus interrupted treatment. Current Alzheimer Research, 8(7), 771–780. https://doi.org/10.2174/156720511797633205

Gorus, E., Lambert, M., De Raedt, R., & Mets, T. (2007). The influence of galantamine on reaction time, attention processes, and performance variability in elderly alzheimer patients. Journal of Clinical Psychopharmacology, 27(2), 182–187. https://doi.org/10.1097/jcp.0b013e318032eadb

Grossberg, G. (2004). Rivastigmine in alzheimer disease: Efficacy over two years. American Journal of Geriatric Psychiatry, 12(4), 420–431. https://doi. org/10.1176/appi.ajgp.12.4.420

Han, S.-H., Lee, J.-H., Kim, S. Y., Park, K. W., Chen, C., Tripathi, M., Dash, A., & Kubota, N. (2016). Donepezil 23 MG in Asian patients with moderate-to-severe alzheimer's disease. Acta Neurologica Scandinavica, 135(2), 252–256. https://doi. org/10.1111/ane.12571

Homma, A., Imai, Y., Tago, H., Asada, T., Shigeta,

M., Iwamoto, T., Takita, M., Arimoto, I., Koma, H., & Ohbayashi, T. (2008). Donepezil treatment of patients with severe alzheimer's disease in a Japanese population: Results from a 24week, double-blind, placebo-controlled, randomized trial. Dementia and Geriatric Cognitive Disorders, 25(5), 399–407. https://doi.org/10.1159/00012 2961

Howard, R., McShane, R., Lindesay, J., Ritchie, C., Baldwin, A., Barber, R., Burns, A., Dening, T., Findlay, D., Holmes, C., Hughes, A., Jacoby, R., Jones, R., Jones, R., McKeith, I., Macharouthu, A., O'Brien, J., Passmore, P., Sheehan, B., ... Phillips, P. (2012). Donepezil and memantine for moderateto-severe alzheimer's disease. New England Journal of Medicine, 366(10), 893–903. https://doi.org/10.1 056/nejmoa1106668

Johannsen, P., Salmon, E., Hampel, H., Xu, Y., Richardson, S., Qvitzau, S., & Schindler, R. (2006). Assessing therapeutic efficacy in a progressive disease. CNS Drugs, 20(4), 311–325. https://doi.org/1 0.2165/00023210-200620040-00005

Jones, R. W., Soininen, H., Hager, K., Aarsland, D., Passmore, P., Murthy, A., Zhang, R., & Bahra, R. (2004). A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate alzheimer's disease. International Journal of Geriatric Psychiatry, 19(1), 58–67. https://doi.org/10.1002/gps.1038

Karaman, Y., Erdoğan, F., Köseoğlu, E., Turan, T., & Ersoy, A. Ö. (2004). A 12-month study of the efficacy of rivastigmine in patients with advanced moderate alzheimer's disease. Dementia and Geriatric Cognitive Disorders, 19(1), 51–56. https://do i.org/10.1159/000080972

Loewenstein, D. A., Acevedo, A., Czaja, S. J., & Duara, R. (2004). Cognitive rehabilitation of mildly impaired alzheimer disease patients on cholinesterase inhibitors. The American Journal of Geriatric Psychiatry, 12(4), 395–402. https://doi.org /10.1097/00019442-200407000-00007

López-Pousa, S., Turon-Estrada, A., Garre-Olmo, J., Pericot-Nierga, I., Lozano-Gallego, M., Vilalta-Franch, M., Hernández-Ferràndiz, M., Morante-Muñoz, V., Isern-Vila, A., Gelada-Batlle, E., & Majó-Llopart, J. (2005). Differential efficacy of treatment with acetylcholinesterase inhibitors in

patients with mild and moderate alzheimer's disease over a 6-month period. Dementia and Geriatric Cognitive Disorders, 19(4), 189–195. https://doi.org/10. 1159/000083498

Lyketsos, C. G., Reichman, W. E., Kershaw, P., & Zhu, Y. (2004). Long-term outcomes of galantamine treatment in patients with alzheimer disease. The American Journal of Geriatric Psychiatry, 12(5), 473–482. https://doi.org/10.1097/00019442-200409 000-00005

Mintzer, J. E., & Kershaw, P. (2003). The efficacy of galantamine in the treatment of alzheimer's disease: Comparison of patients previously treated with acetylcholinesterase inhibitors to patients with no prior exposure. International Journal of Geriatric Psychiatry, 18(4), 292–297. https://doi.org/10.1002/ gps.826

Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009). Preferred reporting items for systematic reviews and meta-analyses: The Prisma statement. PLoS Medicine, 6(7). https://doi.org/10.1371/journal.pmed.1000097

Molinuevo, J. L., Berthier, M. L., & Rami, L. (2011). Donepezil provides greater benefits in mild compared to moderate alzheimer's disease: Implications for early diagnosis and treatment. Archives of Gerontology and Geriatrics, 52(1), 18–22. https://doi.org/ 10.1016/j.archger.2009.11.004

Olazarán, J., Muñiz, R., Reisberg, B., Peña-Casanova, J., del Ser, T., Cruz-Jentoft, A. J., Serrano, P., Navarro, E., García de la Rocha, M. L., Frank, A., Galiano, M., Fernández-Bullido, Y., Serra, J. A., González-Salvador, M. T., & Sevilla, C. (2004). Benefits of cognitive-motor intervention in MCI and mild to moderate alzheimer disease. Neurology, 63(12), 2348–2353. https://doi.org/10.1212/ 01.wnl.0000147478.03911.28

Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., Chou, R., Glanville, J., Grimshaw, J. M., Hróbjartsson, A., Lalu, M. M., Li, T., Loder, E. W., Mayo-Wilson, E., McDonald, S., ... Moher, D. (2021). The Prisma 2020 statement: An updated guideline for reporting systematic reviews. BMJ. https://doi.org/1 0.1136/bmj.n71 Pirttila, T., Wilcock, G., Truyen, L., & Damaraju, C. V. (2004). Long-term efficacy and safety of galantamine in patients with mild-to-moderate alzheimer's disease: Multicenter trial. European Journal of Neurology, 11(11), 734–741. https://doi .org/10.1111/j.1468-1331.2004.00885.x

Porsteinsson, A. P., Isaacson, R. S., Knox, S., Sabbagh, M. N., & Rubino, I. (2021). Diagnosis of early alzheimer's disease: Clinical practice in 2021. The Journal Of Prevention of Alzheimer's Disease, 1–16. https://doi.org/10.14283/jpad.2021.23

Quality Criteria Checklist: Primary Research -Andeal.org. (n.d.). https://www.andeal.org/vault/2 440/web/files/QCC_3.pdf

Richarz, U., Gaudig, M., Rettig, K., & Schauble, B. (2014). Galantamine treatment in outpatients with Mild Alzheimer's disease. Acta Neurologica Scandinavica, 129(6), 382–392. https://doi.org/10.1111/ane.12195

Rozzini, L., Costardi, D., Chilovi, B. V., Franzoni, S., Trabucchi, M., & Padovani, A. (2007). Efficacy of cognitive rehabilitation in patients with mild cognitive impairment treated with cholinesterase inhibitors. International Journal of Geriatric Psychiatry, 22(4), 356–360. https://doi.org/10.1002/gps.16 81

Ryan R, Synnot A, Prictor M, Hill S. Data extraction template for included studies. 2016. https://cccrg.co chrane.org/author-resources

Sabbagh, M., Cummings, J., Christensen, D., Doody, R., Farlow, M., Liu, L., Mackell, J., & Fain, R. (2013). Evaluating the cognitive effects of Donepezil 23 mg/d in moderate and severe alzheimer's disease: Analysis of effects of baseline features on treatment response. BMC Geriatrics, 13(1). https://doi.org/10.1186/1471-2318-13 -56

Silva, M. V., Loures, C. de, Alves, L. C., de Souza, L. C., Borges, K. B., & Carvalho, M. das. (2019). Alzheimer's disease: Risk factors and potentially protective measures. Journal of Biomedical Science, 26(1). https://doi.org/10.1186/s12929-019 -0524-y

Song, J., Ahn, I. S., Kang, H. S., Myung, W., Lee, Y., Woo, S., Ku, H. M., Hwang, T.-Y., Carroll, B. J., & Kim, D. K. (2014). Cognitive subdomain responses

to galantamine in alzheimer's disease. Journal of Nervous & amp; Mental Disease, 202(3), 253–259. https://doi.org/10.1097/nmd.000000000000107

Sun, Y., Lai, M.-S., Lu, C.-J., & Chen, R.-C. (2008). How long can patients with mild or moderate alzheimer's dementia maintain both the cognition and the therapy of cholinesterase inhibitors: A national population-based study. European Journal of Neurology, 15(3), 278–283. https://doi.org/10.1 111/j.1468-1331.2007.02049.x

Ulep, M. G., Saraon, S. K., & McLea, S. (2018). Alzheimer disease. The Journal for Nurse Practitioners, 14(3), 129–135. https://doi.org/10.1016/j.nurpr a.2017.10.014

Wallin, Å. K., Andreasen, N., Eriksson, S., Båtsman, S., Näsman, B., Ekdahl, A., Kilander, L., Grut, M., Rydén, M., Wallin, A., Jonsson, M., Olofsson, H., Londos, E., Wattmo, C., Eriksdotter Jönhagen, M., & Minthon, L. (2006). Donepezil in alzheimer's disease: What to expect after 3 years of treatment in a routine clinical setting. Dementia and Geriatric Cognitive Disorders, 23(3), 150–160. https://doi.org/10. 1159/000098052

Wattmo, C., Wallin, Å. K., & Minthon, L. (2012). Functional response to cholinesterase inhibitor therapy in a naturalistic alzheimer's disease cohort. BMC Neurology, 12(1). https://doi.org/10.1186/1471-237 7-12-134

Wilcock, G., Howe, I., Coles, H., Lilienfeld, S.,

Truyen, L., Zhu, Y., & Bullock, R. (2003). A longterm comparison of galantamine and Donepezil in the treatment of alzheimer's disease. Drugs & amp; Aging, 20(10), 777–789. https://doi.org/10.2165/00 002512-200320100-00006

Winblad, B., Kilander, L., Eriksson, S., Minthon, L., Båtsman, S., Wetterholm, A.-L., Jansson-Blixt, C., & Haglund, A. (2006). Donepezil in patients with severe alzheimer's disease: Doubleblind, parallel-group, placebo-controlled study. The Lancet, 367(9516), 1057–1065. https://doi.org/10.1 016/s0140-6736(06)68350-5

Xu, H., Garcia-Ptacek, S., Jönsson, L., Wimo, A., Nordström, P., & Eriksdotter, M. (2021). Longterm effects of cholinesterase inhibitors on cognitive decline and mortality. Neurology, 96(17). https://do i.org/10.1212/wnl.000000000011832

How to cite this article: Meziou L., Haubrick K. A Systematic Review of the Effectiveness of Acetylcholinesterase Inhibitors on Cognition for Patients with Alzheimer's Disease. Research Review (Wilmington, N.C.). 2024;2618–2639. h ttps://doi.org/10.52845/RR/2024-5-6-1

AUTHOR BIOGRAPHY

Lena Meziou Houston, TX 77012